Volumizing lax skin does not fail first as a matter of taste. It fails first as a matter of arithmetic, and the arithmetic is worth doing out loud with a patient — and with yourself — before you open the second syringe.
One millilitre of filler is roughly the size of a blueberry. That is the whole argument in one sentence, and it is the sentence I use at the chairside, because a patient who has been told a syringe is "a millilitre" has no mental image at all, whereas every patient knows how big a blueberry is.
Then comes the question that should stop the treatment plan: if that is how much is in one syringe, how many syringes would it take to fill skin that has lost its elasticity and now hangs? Work that number honestly and you arrive somewhere uncomfortable. And when injectors supply it anyway — a little more this visit, a little more the next — that is when we start changing people's faces.
The arithmetic, checked
The blueberry comparison is not a marketing line. It survives being checked.
The US Standards for Grades of Blueberries classify berry size by count per cup: extra large is fewer than 90 berries per cup, large is 90 to 129, medium is 130 to 189, and small is 190 to 250 (USDA Agricultural Marketing Service, §51.3477). A US cup is 236.6 mL, and loosely packed near-spheres occupy roughly 60% of the container they sit in, the rest being air between berries. That puts about 140 mL of actual berry in a cup.
Run it out: a medium berry is roughly 0.75 to 1.1 mL. A large berry is roughly 1.1 to 1.6 mL. Cross-check it geometrically and a perfect 1 mL sphere has a diameter of 12.4 mm, which is a completely ordinary cultivated blueberry.
So: one syringe of filler is about one medium-to-large blueberry. If you want a second reference point, 1 mL is one-fifth of a teaspoon.
Hold that image while you look at a face.
Now count what laxity would require
Here is where the honest answer is uncomfortable, and where most product-led planning quietly avoids going.
There is no dose of filler that eliminates facial laxity, and that is not because nobody has looked. Volume does not restore elastic recoil. It is the wrong intervention for the finding, so the number you are looking for does not exist at any figure.
What does exist is the dose at which the face changes. A lax lower face, assessed at rest, can appear to improve with one or two millilitres — for about a fortnight, in a mirror, under favourable light. The patient wants a bit more. Two visits later you are at four or five millilitres in a region whose problem was never a deficit of four or five millilitres of anything. You have added the equivalent of five blueberries to the lower third of a face, and the skin that was hanging is now hanging over a larger object.
The tell is animation. Filler is placed with the face at rest and assessed with the face at rest, and a review in Clinical, Cosmetic and Investigational Dermatology describes the consequence precisely: on smiling, the midface fat compartments and the injected material protrude forward together, and an excessive volume amplifies that forward shift, producing a midface that looks disproportionate in motion even when it looked acceptable still (Zhou C, Che Q, Zhao R, Wang H, Wa Q. Clin Cosmet Investig Dermatol. 2026;19:doi:10.2147/CCID.S600459). The same review notes the more troubling long-run observation: excessive filler injection may itself further decrease skin elasticity. The treatment for laxity can make laxity worse.
More product does not buy more lift
If you take one piece of published evidence from this article into your next consultation, make it this one, because it undermines the commercial logic of escalation from the inside.
A 2026 critical review in JPRAS Open examined how "lift" is actually operationalised across the soft tissue filler literature — hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, polycaprolactone and hybrid products. The findings are blunt. "Lift" has no consensus operational definition. Every published quantitative measurement tracks displacement at the skin surface rather than independently tracking deeper structures. The reported millimetre-scale effects are frequently of the same order as the standard deviation of the measurement and the documented accuracy of the imaging modality used, and in some cases are exceeded by it. Studies comparing rater groups suggest less independent raters report larger improvements. And, critically for this argument: where dose–response analyses were performed, they demonstrated a non-monotonic relationship between injected volume and measured displacement, not a dose-dependent one (Harris S, Michon A. JPRAS Open. 2026;51:646–656. doi:10.1016/j.jpra.2026.07.028).
Non-monotonic means the curve does not keep going up. Past some point, adding volume stops adding the thing you were adding it for.
The authors are careful, and so should we be: this does not establish that fillers do not lift. It establishes that the construct of filler-mediated lift has not been operationalised with anything like the precision its commercial claims now require. That is a narrower statement, and it is still enough to change what you do on Monday morning. If you cannot demonstrate that the fourth millilitre does more than the third, the decision to inject it is not a clinical one.
What actually happens to the face
Over-volumisation is not one phenomenon. It has recognised patterns, and being able to name them makes them easier to see in your own work.
Kapoor's classification of facial overfilled syndrome, summarised in the review above, describes five:
- Focal superficial overfilling — excessive or improperly superficial injection, made worse by repeat touch-ups performed before the previous product has degraded.
- Global superficial overfilling — frequent use of skin enhancers and hydrating fillers without any volumetric assessment. Note that this one arrives through the "gentle, natural" door, not the obvious one.
- Deep volume overfilling — extensive use of high-G′ product for structural effect, without accounting for its long-term residual properties.
- Myomodulatory overfilling — highly elastic or large-volume product placed over expression muscles, restricting them.
- Chronic layered overfilling — low-grade inflammation, product migration and long-term accumulation producing fibrotic remodelling.
Patients move between subtypes over time as exposure accumulates. Alongside these run the effects any injector can observe: loss of the natural relationship between features, a face that reads as bloated and stiff rather than rested, midface protrusion that makes the chin and forehead look relatively recessed, surface irregularity, and the psychological consequence of a patient who no longer recognises themselves.
That last one is the thing patients actually fear. They are not afraid of looking older. They are afraid of looking different — of walking into a room and having someone register that something has been done. Every over-treatment decision is a bet against that fear, made on their behalf, usually without saying so.
Why neither of you notices
The reason this happens to competent, well-intentioned injectors is not greed. It is perception.
A 2026 review in Clinical, Cosmetic and Investigational Dermatology proposes the concept of Professional Aesthetic Drift: a progressive shift in a clinician's aesthetic perception, judgement and treatment thresholds resulting from chronic exposure to altered facial morphologies, procedural repetition, and algorithm-driven social media environments (Armenti AF. Clin Cosmet Investig Dermatol. 2026;19:doi:10.2147/CCID.S583396). The framework draws on visual neuroscience and perceptual adaptation: look at enough treated faces and treated faces become your normal.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
It is a theoretical framework rather than a measured effect, and should be read that way. But it names something every experienced injector will recognise if they are honest — the volume that felt like a lot in year one feels like a starting point in year six. Meanwhile the patient is experiencing the mirror version of the same thing: when a face is frequently and gradually altered, visual adaptation makes the change invisible from the inside.
Two people in a room, neither of whom can see it. That is the mechanism.
What to do instead
The alternative is not doing less for its own sake. It is doing the thing that matches the finding.
Diagnose laxity as laxity. Pinch and release the lateral cheek or pre-jowl skin. Prompt recoil means quality work is worth doing. Slow recoil or tenting means you are looking at an elasticity problem, and an elasticity problem does not have a volumetric answer.
Treat the lower face with proportion, not volume. The lower face is where over-volumisation does the most damage, because added weight there reads as heaviness and heaviness reads as age. The combination I use in that region is a little filler where support has genuinely been lost, plus a biostimulator to work on tissue quality — not more of the first thing.
Under-correct on purpose. Not because you are being cautious, but because you can always add at the review visit and you cannot always remove. This is also what the labelling for injectable poly-L-lactic acid explicitly instructs: under-correct the deficiency, never fully correct or over-correct at any single session.
Stage across visits and reassess with photographs. Standardised images, same framing, same light, compared side by side. This is your only defence against your own drift, because the camera does not adapt.
Say the number out loud. "That's about a blueberry" is a more honest description of one syringe than any volume figure, and it reframes the question from "do you want more" to "do you want a bigger face". Most patients, asked the second question, say no.
Assess in animation before you finish. If the face is acceptable at rest and wrong on a smile, you are already past the point.
These clinical approaches, ratios and volumes reflect Maritza Mejia's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.
The commercial objection, answered
The obvious response to all of this is that it argues against selling product, which is how an aesthetic practice pays for itself.
Two things are true at once. First, the escalation model has a terminal state: a cohort of patients whose faces have been changed, who eventually notice, and who leave — frequently to someone who dissolves your work. Empire has a patient-facing page on dissolving filler and the demand for it is not accidental. Second, the alternative is not fewer treatments. It is different treatments. A patient on a staged plan combining modest structural correction with biostimulator work and skin quality treatment, reviewed and re-photographed and continued over years, is worth more to a practice than a patient who bought five syringes in eighteen months and then disappeared.
Restraint is not a smaller business. It is a longer one.
Where this is trained
Judging how much is enough is not a thing you can read your way into. It is built by injecting under supervision, being stopped, and being shown the difference between a correction and an over-correction on a real face. Empire's Complete Dermal Filler Training covers the structural half of the decision and Anatomical Based Aesthetics Training covers the planes that determine whether a given volume reads as support or as bulk. For the combination approach that lets you stop answering every finding with volume, the Facial Contouring Injectables workshop covering Sculptra, Radiesse, exosomes and PDRN is the relevant course. For patients who arrive asking what a full plan costs, send them to Empire's collagen injection cost page rather than improvising figures in the room.
Frequently Asked Questions
Is one millilitre really the size of a blueberry?
Close enough to use clinically, and it checks out. USDA blueberry grade standards classify a medium berry at 130 to 189 per cup and a large berry at 90 to 129; allowing for the air between packed berries, that puts a medium berry at roughly 0.75 to 1.1 mL and a large one at 1.1 to 1.6 mL. A perfect 1 mL sphere is 12.4 mm across, which is an ordinary blueberry.
How much filler is too much for a lower face?
Judge by finding rather than by millilitres, because the finding is what decides it: if the complaint is descent or laxity rather than a specific contour deficit, the correct volume may be close to zero. Assess in animation before you finish, because the lower face fails on movement before it fails at rest.
Can adding volume make laxity worse?
Published review work raises exactly that concern — excessive filler injection may further reduce skin elasticity, and repeated cycles of distension and partial resorption are a plausible mechanism. It is not a settled quantitative finding, but it is a serious enough possibility that "more volume" should never be the default response to a laxity complaint.
If more product does not mean more lift, why do results improve at first?
Because the early millilitres are doing a genuine job: restoring a real contour deficit in a specific compartment. The published dose–response analyses show the relationship between volume and measured displacement is non-monotonic, meaning the curve flattens and can reverse. The first syringe and the fifth are not doing the same thing.
How do I avoid drifting without noticing?
Standardised photography, compared at intervals, against the patient's own baseline rather than against your current sense of normal. Review your own before-and-afters from several years ago. And use a second opinion for faces you have treated many times, because perceptual adaptation is not something you can detect from inside it.
Disclaimer
This article reflects the clinical opinions and experience of Maritza Mejia, FNP, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
